Biohaven Pharmaceutical Holding Co. Ltd., of New Haven, Conn., said it completed randomization of it phase II/III trial testing trigriluzole (previously known as BHV-4157) in 141 patients with spinocerebellar ataxia. The trial compares trigriluzole, a glutamate modulator, to placebo, measuring the change from baseline in patient scores on the Scale for the Assessment and Rating of Ataxia after eight weeks of treatment. Biohaven expects top-line data from the trial in the fourth quarter.